Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Hyku Biosciences is developing small molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression. To achieve this goal, we are pioneering our proprietary Hyku platform, which identifies compounds that covalently bind non-cysteine amino acids to facilitate the development of novel therapies that can address current challenges associated with many disease targets, includin...
Hyku Biosciences is developing small molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression. To achieve this goal, we are pioneering our proprietary Hyku platform, which identifies compounds that covalently bind non-cysteine amino acids to facilitate the development of novel therapies that can address current challenges associated with many disease targets, including selectivity, druggability, and resistance.

List your booth number for exhibitions, ask us